Literature DB >> 31178295

Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care.

Llorenç Caballeria1, Salvador Augustin2, Teresa Broquetas3, Rosa Maria Morillas4, Mercè Vergara5, Silvia Virolés6, Mª Rosario Hernández7, Isabel Serra8, Alberto Goday9, Lluis Vila10, Antonio Siso-Almirall11, Rosa Solans12, Jose Manuel Fernández-Real13, Jose Antonio Carrión3, Isabel Graupera14, Pere Ginès15.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, with a prevalence of 20-30% in the general population and 60-80% in at-risk populations. In a not negligible percentage of patients, NAFLD progresses from steatosis to different stages of fibrosis and cirrhosis. Due to its high prevalence, NAFLD has become a significant health problem that requires specific action in detection, diagnosis, follow-up and treatment. Furthermore, given that NAFLD presents an increased risk of cardiovascular morbidity and mortality, a multidisciplinary approach is required for its treatment and follow-up. Patients with early stages of the disease, without fibrosis, can be diagnosed and receive treatment in the Primary Care setting, while those with more advanced liver disease benefit from specialised follow-up in the hospital setting to prevent and treat liver complications. This consensus document, prepared by the Catalan Societies of Digestology, Primary Care, Endocrinology, Diabetes and Internal Medicine, arises from the need to design strategies to guide patient flows between Primary and Hospital Care in order to offer patients with NAFLD the best care according to the stage of their disease. The consensus document describes the most commonly used non-invasive diagnostic methods for patient diagnosis and two algorithms have been designed for patient management in both Primary Care and Hospital Care.
Copyright © 2019 The Authors. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Cirrosis; Elastografía; Elastography; Esteatohepatitis; Esteatosis; Steatohepatitis; Steatosis

Mesh:

Year:  2019        PMID: 31178295     DOI: 10.1016/j.medcli.2019.01.030

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  4 in total

Review 1.  Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico.

Authors:  Paulina Vidal-Cevallos; Aldo Torre; Nahum Mendez-Sanchez; Misael Uribe; Norberto C Chavez-Tapia
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-03-10

Review 2.  Identification of liver disease: why and how.

Authors:  Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman
Journal:  Frontline Gastroenterol       Date:  2022-01-24

3.  [The fatty liver epidemic: An analysis from the primary care].

Authors:  Llorenç Caballeria; Pere Torán
Journal:  Aten Primaria       Date:  2019-11       Impact factor: 1.137

4.  Risk of Liver Fibrosis According to TSH Levels in Euthyroid Subjects.

Authors:  Alba Martínez-Escudé; Guillem Pera; Lluís Rodríguez; Ingrid Arteaga; Carmen Expósito-Martínez; Pere Torán-Monserrat; Llorenç Caballería
Journal:  J Clin Med       Date:  2021-03-25       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.